NCT00559949View on ClinicalTrials.gov

Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Recurrent Thyroid Gland CarcinomaStage I Thyroid Gland Papillary CarcinomaStage II Thyroid Gland Papillary CarcinomaStage III Thyroid Gland Papillary CarcinomaStage IV Thyroid Gland Papillary Carcinoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Selumetinib

Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.

Trial Locations (6)

19111

Fox Chase Cancer Center, Philadelphia

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University/Ingram Cancer Center, Nashville

60637

University of Chicago Comprehensive Cancer Center, Chicago

M5G 2M9

University Health Network-Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00559949 - Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | Biotech Hunter | Biotech Hunter